Chronic Idiopathic Constipation (CIC) Treatment Market, By Drug Type Linaclotide, Plecanatide

Constipation is condition wherein the stool frequency reduces up to three times per week with difficulty in stool passing. Chronic constipation is a highly common functional gastrointestinal disorder that adversely affects patient’s life. Chronic idiopathic constipation is defined as the presence of chronic symptoms of constipation with no well-defined underlying cause. The symptoms of chronic idiopathic constipation includes infrequent bowel movements, hard stools, straining during defecation, feeling of incomplete evacuation, abdominal discomfort, and bloating sensation. Chronic idiopathic constipation is diagnosed by laboratory tests, endoscopy, radiological tests, magnetic resonance imaging, and physiological testing. Currently, very few approved treatment options are available for chronic idiopathic constipation, which is expected to be a major factor restrain growth of the chronic idiopathic constipation treatment market. However, this gives opportunity for the market player to come up with the novel treatment to grab the foothold in growing chronic idiopathic constipation treatment market.

Click To Continue Reading :

https://www.coherentmarketinsights.com/ongoing-insight/chronic-idiopathic-constipation-cic-treatment-market-1791

Chronic Idiopathic Constipation (CIC) Treatment Market Dynamics

Increasing clinical trials and approval of drug candidates by pharmaceutical companies to fulfil unmet medical needs of the chronic idiopathic constipation treatment is a key factor driving the market growth over the forecast period. For instance, March 2018, Shire plc received new drug application from U.S. FDA for its drug candidate, SHP555 (prucalopride) for the indication of chronic idiopathic constipation in adults. Moreover, in 2015, SHP555 (prucalopride)received approval from European Commission for the symptomatic treatment of chronic constipation in adults with failure of laxative treatment. Furthermore, Renexxion is conducting phase 2 clinical trial for Naronapride (ATI-7505) for the treatment of multiple gastrointestinal disorders, which includes chronic idiopathic constipation. In 2017, FDA approved Ironwood and Allergan’s Linzess (linaclotide) for the treatment of chronic idiopathic constipation. However, 50% of patients with chronic constipation dissatisfied with their current treatment, mainly because of the lack of efficacy, which highlights a continued medical need for more effective and safer therapeutic agents.

Get The Holistic SAMPLE With Research Methodology:

https://www.coherentmarketinsights.com/insight/request-sample/1791

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Visit our news Website:https://www.coherenttimes.org

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging